{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:42:35Z","timestamp":1778902955482,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular and Cellular Neuroscience"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.mcn.2021.103641","type":"journal-article","created":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T19:11:37Z","timestamp":1622833897000},"page":"103641","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer's disease"],"prefix":"10.1016","volume":"114","author":[{"given":"Malin","family":"Johannesson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Sahlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"S\u00f6derberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Basun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"F\u00e4lting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christer","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olof","family":"Zachrisson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Sunnemark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Svensson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Odergren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Lannfelt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcn.2021.103641_bb0005","article-title":"Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain","author":"Alic","year":"2020","journal-title":"Mol. Psychiatry"},{"issue":"5","key":"10.1016\/j.mcn.2021.103641_bb0010","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jalz.2015.07.490","article-title":"The pattern of amyloid accumulation in the brains of adults with Down syndrome","volume":"12","author":"Annus","year":"2016","journal-title":"Alzheimers Dement."},{"issue":"7","key":"10.1016\/j.mcn.2021.103641_bb0015","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1248\/yakushi.16-00236-2","article-title":"Elucidating Pathogenic Mechanisms of Early-onset Alzheimer\u2019s Disease in Down Syndrome Patients","volume":"137","author":"Asai","year":"2017","journal-title":"Yakugaku Zasshi"},{"issue":"5","key":"10.1016\/j.mcn.2021.103641_bb0020","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/0197-4580(92)90065-6","article-title":"Methodological variables in the assessment of beta amyloid neurotoxicity","volume":"13","author":"Busciglio","year":"1992","journal-title":"Neurobiol. Aging"},{"issue":"3","key":"10.1016\/j.mcn.2021.103641_bb0025","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0197-4580(95)00013-5","article-title":"Correlations of synaptic and pathological markers with cognition of the elderly","volume":"16","author":"Dickson","year":"1995","journal-title":"Neurobiol. Aging"},{"issue":"2","key":"10.1016\/j.mcn.2021.103641_bb0030","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3233\/JAD-160836","article-title":"Down syndrome, partial trisomy 21, and absence of Alzheimer\u2019s disease: the role of APP","volume":"56","author":"Doran","year":"2017","journal-title":"J. Alzheimers Dis."},{"issue":"1","key":"10.1016\/j.mcn.2021.103641_bb0035","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1471-4159.2007.04759.x","article-title":"Sensitive ELISA detection of amyloid-beta protofibrils in biological samples","volume":"103","author":"Englund","year":"2007","journal-title":"J. Neurochem."},{"issue":"10","key":"10.1016\/j.mcn.2021.103641_bb0040","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S1474-4422(18)30285-0","article-title":"Plasma and CSF biomarkers for the diagnosis of Alzheimer\u2019s disease in adults with Down syndrome: a cross-sectional study","volume":"17","author":"Fortea","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.mcn.2021.103641_bb0045","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.nbd.2017.06.010","article-title":"Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer\u2019s disease phenotypes","volume":"106","author":"Garc\u00eda-Cerro","year":"2017","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.mcn.2021.103641_bb0050","doi-asserted-by":"crossref","unstructured":"Gkanatsiou E, Sahlin C, Portelius E, Johannesson M, S\u00f6derberg L, F\u00e4lting J, Basun H, M\u00f6ller C, Odergren T, Zetterberg H, Blennow K, Lannfelt L, Brinkmalm G. Characterization of monomeric and soluble aggregated A\u03b2 in Down syndrome and Alzheimer's disease brains. 2021 Neurosci. Lett. 135894. doi: https:\/\/doi.org\/10.1016\/j.neulet.2021.135894.","DOI":"10.1016\/j.neulet.2021.135894"},{"issue":"1","key":"10.1016\/j.mcn.2021.103641_bb0055","doi-asserted-by":"crossref","first-page":"7","DOI":"10.31887\/DCNS.2016.18.1\/shaber","article-title":"Corticostriatal circuitry","volume":"18","author":"Haber","year":"2016","journal-title":"Dialogues Clin. Neurosci."},{"issue":"20","key":"10.1016\/j.mcn.2021.103641_bb0060","doi-asserted-by":"crossref","first-page":"8876","DOI":"10.1523\/JNEUROSCI.19-20-08876.1999","article-title":"Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons","volume":"19","author":"Hartley","year":"1999","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.mcn.2021.103641_bb0065","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2174\/1567205012666151020114607","article-title":"Aging in down syndrome and the development of Alzheimer\u2019s disease neuropathology","volume":"13","author":"Head","year":"2016","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.mcn.2021.103641_bb0070","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.freeradbiomed.2017.09.013","article-title":"Down syndrome, beta-amyloid and neuroimaging","volume":"114","author":"Head","year":"2018","journal-title":"Free Radic. Biol. Med."},{"issue":"4","key":"10.1016\/j.mcn.2021.103641_bb0075","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/archneur.1995.00540280065020","article-title":"Age-related distribution of neuropathologic changes in the cerebral cortex of patients with Down syndrome. Quantitative regional analysis and comparison with Alzheimer\u2019s disease","volume":"52","author":"Hof","year":"1995","journal-title":"Arch. Neurol."},{"issue":"6","key":"10.1016\/j.mcn.2021.103641_bb0080","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1212\/01.WNL.0000115115.98960.37","article-title":"Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain","volume":"62","author":"Ingelsson","year":"2004","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.mcn.2021.103641_bb0085","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1111\/j.1742-4658.2006.05263.x","article-title":"Physiochemical characterization of the Alzheimer\u2019s disease-related peptides A beta 1-42Arctic and A beta 1-42wt","volume":"273","author":"Johansson","year":"2006","journal-title":"FEBS J."},{"issue":"3","key":"10.1016\/j.mcn.2021.103641_bb0090","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/j.1471-4159.2010.06812.x","article-title":"Characterization of AZD4694, a novel fluorinated Abeta plaque neuroimaging PET radioligand","volume":"114","author":"Jur\u00e9us","year":"2010","journal-title":"J. Neurochem."},{"issue":"29","key":"10.1016\/j.mcn.2021.103641_bb0095","doi-asserted-by":"crossref","first-page":"12031","DOI":"10.1073\/pnas.0813248106","article-title":"The genetic architecture of Down syndrome phenotypes revealed by high-resolution analysis of human segmental trisomies","volume":"106","author":"Korbel","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mcn.2021.103641_bb0100","doi-asserted-by":"crossref","unstructured":"Lannfelt L, M\u00f6ller C, Basun H, et al. Perspectives on future Alzheimer therapies: amyloid-\u03b2 protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease. Alzheimers Res Ther. 2014;6(2):16. Published 2014 Mar 24. doi:https:\/\/doi.org\/10.1186\/alzrt246.","DOI":"10.1186\/alzrt246"},{"key":"10.1016\/j.mcn.2021.103641_bb0105","doi-asserted-by":"crossref","unstructured":"Lao PJ, Handen BL, Betthauser TJ, et al. Longitudinal changes in amyloid positron emission tomography and volumetric magnetic resonance imaging in the nondemented Down syndrome population. Alzheimers Dement (Amst). 2017;9:1-9. Published 2017 May 23. doi:https:\/\/doi.org\/10.1016\/j.dadm.2017.05.001.","DOI":"10.1016\/j.dadm.2017.05.001"},{"key":"10.1016\/j.mcn.2021.103641_bb0110","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.neurobiolaging.2017.03.005","article-title":"Down syndrome: age-dependence of PiB binding in postmortem frontal cortex across the lifespan","volume":"54","author":"LeVine","year":"2017","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.mcn.2021.103641_bb0115","doi-asserted-by":"crossref","unstructured":"Logovinsky V, Satlin A, Lai R, et al. Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective A\u03b2 antibody. Alzheimers Res Ther. 2016;8(1):14. Published 2016 Apr 6. doi:https:\/\/doi.org\/10.1186\/s13195-016-0181-2.","DOI":"10.1186\/s13195-016-0181-2"},{"issue":"1","key":"10.1016\/j.mcn.2021.103641_bb0120","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3233\/JAD-130029","article-title":"Specific uptake of an amyloid-\u03b2 protofibril-binding antibody-tracer in A\u03b2PP transgenic mouse brain","volume":"37","author":"Magnusson","year":"2013","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.mcn.2021.103641_bb0125","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00401-018-1866-3","article-title":"Patterns and severity of vascular amyloid in Alzheimer\u2019s disease associated with duplications and missense mutations in APP gene, Down syndrome and sporadic Alzheimer\u2019s disease","volume":"136","author":"Mann","year":"2018","journal-title":"Acta Neuropathol."},{"issue":"7","key":"10.1016\/j.mcn.2021.103641_bb0130","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1001\/jamaneurol.2019.0765","article-title":"Association between longitudinal plasma neurofilament light and neurodegeneration in patients with alzheimer disease [published correction appears in JAMA Neurol. 2019 Jun 10;:]","volume":"76","author":"Mattsson","year":"2019","journal-title":"JAMA Neurol."},{"issue":"12","key":"10.1016\/j.mcn.2021.103641_bb0135","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jama.283.12.1571","article-title":"Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline","volume":"283","author":"N\u00e4slund","year":"2000","journal-title":"JAMA."},{"issue":"19","key":"10.1016\/j.mcn.2021.103641_bb0140","doi-asserted-by":"crossref","first-page":"6115","DOI":"10.1021\/bi015985r","article-title":"Growth of beta-amyloid(1-40) protofibrils by monomer elongation and lateral association. Characterization of distinct products by light scattering and atomic force microscopy","volume":"41","author":"Nichols","year":"2002","journal-title":"Biochemistry."},{"issue":"9","key":"10.1016\/j.mcn.2021.103641_bb0145","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nn0901-887","article-title":"The \u2018Arctic\u2019 APP mutation (E693G) causes Alzheimer\u2019s disease by enhanced Abeta protofibril formation","volume":"4","author":"Nilsberth","year":"2001","journal-title":"Nat. Neurosci."},{"issue":"10","key":"10.1016\/j.mcn.2021.103641_bb0150","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.neurobiolaging.2006.06.023","article-title":"Alpha- and beta-secretase activity as a function of age and beta-amyloid in Down syndrome and normal brain","volume":"28","author":"Nistor","year":"2007","journal-title":"Neurobiol. Aging"},{"issue":"1\u20132","key":"10.1016\/j.mcn.2021.103641_bb0155","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0006-8993(91)91553-D","article-title":"In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity","volume":"563","author":"Pike","year":"1991","journal-title":"Brain Res."},{"issue":"3","key":"10.1016\/j.mcn.2021.103641_bb0160","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/ana.410430316","article-title":"Molecular mapping of Alzheimer-type dementia in Down syndrome","volume":"43","author":"Prasher","year":"1998","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.mcn.2021.103641_bb0165","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/B978-0-12-804766-8.00017-0","article-title":"Down syndrome","volume":"167","author":"Rafii","year":"2019","journal-title":"Handb. Clin. Neurol."},{"issue":"3","key":"10.1016\/j.mcn.2021.103641_bb0170","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/archneur.65.3.412","article-title":"Mosaicism for trisomy 21 in a patient with young-onset dementia: a case report and brief literature review","volume":"65","author":"Ringman","year":"2008","journal-title":"Arch. Neurol."},{"issue":"4","key":"10.1016\/j.mcn.2021.103641_bb0175","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00401-009-0530-3","article-title":"A fibril-specific, conformation-dependent antibody recognizes a subset of Abeta plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain","volume":"118","author":"Sarsoza","year":"2009","journal-title":"Acta Neuropathol."},{"issue":"2","key":"10.1016\/j.mcn.2021.103641_bb0180","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3233\/JAD-170624","article-title":"Predictors of age of diagnosis and survival of Alzheimer\u2019s disease in down syndrome","volume":"61","author":"Sinai","year":"2018","journal-title":"J. Alzheimers Dis."},{"issue":"4","key":"10.1016\/j.mcn.2021.103641_bb0185","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/ana.410300410","article-title":"Physical basis of cognitive alterations in Alzheimer\u2019s disease: synapse loss is the major correlate of cognitive impairment","volume":"30","author":"Terry","year":"1991","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.mcn.2021.103641_bb0190","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3233\/JAD-140741","article-title":"The murine version of BAN2401 (mAb158) selectively reduces amyloid-\u03b2 protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice","volume":"43","author":"Tucker","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.mcn.2021.103641_bb0195","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.neurobiolaging.2018.09.030","article-title":"Comparison of longitudinal A\u03b2 in nondemented elderly and Down syndrome","volume":"73","author":"Tudorascu","year":"2019","journal-title":"Neurobiol. Aging"},{"issue":"35","key":"10.1016\/j.mcn.2021.103641_bb0200","doi-asserted-by":"crossref","first-page":"22364","DOI":"10.1074\/jbc.272.35.22364","article-title":"Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate","volume":"272","author":"Walsh","year":"1997","journal-title":"J. Biol. Chem."}],"container-title":["Molecular and Cellular Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044743121000543?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044743121000543?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T01:10:05Z","timestamp":1760922605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044743121000543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":40,"alternative-id":["S1044743121000543"],"URL":"https:\/\/doi.org\/10.1016\/j.mcn.2021.103641","relation":{},"ISSN":["1044-7431"],"issn-type":[{"value":"1044-7431","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"Molecular and Cellular Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcn.2021.103641","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103641"}}